EAGLE, Idaho, June 01, 2023 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication and wellness company, today announced members of the management team will participate in two upcoming June investor conferences.
Wednesday, June 7, 2023 -- William Blair 43rd Annual Growth Stock Conference: The presentation is scheduled for 8:00 a.m. Eastern Time.
Tuesday, June 13, 2023 -- Oppenheimer 23rd Annual Consumer Growth & E-Commerce Virtual Conference: The fireside chat is scheduled for 2:15 p.m. Eastern Time.
The conference presentation and fireside chat will be webcasted and can be accessed live or archived over the Internet hosted at the “Investors” section of the Company's website at www.PetIQ.com.
About PetIQ
PetIQ is a leading pet medication and wellness company delivering a smarter way for pet parents to help their pets live their best lives through convenient access to affordable veterinary products and services. The Company engages with customers through more than 60,000 points of distribution across retail and e-commerce channels with its branded and distributed medications as well as health and wellness items, which are further supported by its world-class medications manufacturing facility in Omaha, Nebraska and health and wellness manufacturing facility in Springville, Utah. The Company’s national service platform operates in over 2,600 retail partner locations in 41 states providing cost effective and convenient veterinary wellness services. PetIQ believes that pets are an important part of the family and deserve the best products and care we can give them.
Investors: This email address is being protected from spambots. You need JavaScript enabled to view it. or 208.513.1513
Media: This email address is being protected from spambots. You need JavaScript enabled to view it. or 407.929.6727
Last Trade: | US$30.98 |
Daily Volume: | 0 |
Market Cap: | US$919.180M |
August 07, 2024 May 08, 2024 March 14, 2024 February 28, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load